Merus Labs International Company Profile (NASDAQ:MSLI)

About Merus Labs International

Merus Labs International logoMerus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women's health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MSLI
  • CUSIP:
Key Metrics:
  • Previous Close: $0.96
  • 50 Day Moving Average: $1.00
  • 200 Day Moving Average: $1.22
  • 52-Week Range: $0.92 - $1.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 24.00
  • P/E Growth: 0.00
  • Market Cap: $112.32M
  • Outstanding Shares: 116,999,000
  • Beta: 1.68
  • Net Margins: -12.89%
  • Return on Equity: -3.41%
  • Return on Assets: -2.03%
  • Debt-to-Equity Ratio: 0.61%
  • Current Ratio: 0.80%
  • Quick Ratio: 0.56%
Additional Links:
Companies Related to Merus Labs International:

Analyst Ratings

Consensus Ratings for Merus Labs International (NASDAQ:MSLI) (?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $4.41 (359.82% upside)

Analysts' Ratings History for Merus Labs International (NASDAQ:MSLI)
DateFirmActionRatingPrice TargetDetails
10/5/2016Paradigm CapitalReiterated RatingHold$1.75 -> $1.60View Rating Details
8/12/2016Canaccord GenuityReiterated RatingBuyView Rating Details
6/13/2016WedbushReiterated RatingOutperformView Rating Details
6/13/2016GuggenheimReiterated RatingBuyView Rating Details
6/13/2016Citigroup Inc.Reiterated RatingBuy$14.00View Rating Details
3/4/2016ScotiabankReiterated RatingSector Perform$2.75 -> $2.25View Rating Details
2/5/2016MackieReiterated RatingHold$1.90 -> $2.30View Rating Details
2/5/2016Dundee SecuritiesReiterated RatingBuy$3.50 -> $3.60View Rating Details
11/30/2015Royal Bank Of CanadaReiterated RatingSector Outperform$2.90View Rating Details
11/30/2015CIBCInitiated CoverageSector Outperform -> OutperformView Rating Details
5/29/2015TD SecuritiesInitiated CoverageBuyView Rating Details
5/26/2015LB SecuritiesReiterated RatingBuy$3.50 -> $3.75View Rating Details
11/18/2014Laurentian Bank of CanadaInitiated CoverageBuy$3.00View Rating Details
(Data available from 10/28/2014 forward)


Earnings History for Merus Labs International (NASDAQ:MSLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/15/2016Q316($0.01)($0.04)$19.58 millionViewN/AView Earnings Details
12/18/2014($0.01)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merus Labs International (NASDAQ:MSLI)
Current Year EPS Consensus Estimate: $-0.06 EPS
Next Year EPS Consensus Estimate: $0.04 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.00$0.06$0.03
Q2 20165($0.01)$0.07$0.02
Q3 20163$0.01$0.06$0.04
Q4 20161$0.00$0.00$0.00
Q1 20171$0.00$0.00$0.00
Q2 20172$0.01$0.02$0.02
Q3 20173$0.01$0.02$0.02
(Data provided by Zacks Investment Research)


Dividend History for Merus Labs International (NASDAQ:MSLI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merus Labs International (NASDAQ:MSLI)
No insider trades for this company have been tracked by


Latest Headlines for Merus Labs International (NASDAQ:MSLI)
News IconAurora Cannabis Adds Pharmaceutical Industry Veteran to Board of Directors (NASDAQ:MSLI) - October 13 at 9:49 AM logoBarry Fishman Joins Aurora Board as Independent Director (NASDAQ:MSLI) - October 12 at 11:35 AM logoMerus Labs Announces Reduced Interest Rate on Senior Secured Debt and Reduced Leverage (NASDAQ:MSLI) - October 3 at 10:50 AM
News IconMerus Labs (MSLI) Tanks on Weak Q3 Financial Results (NASDAQ:MSLI) - August 15 at 6:31 PM logoMerus Labs reports 3Q loss (NASDAQ:MSLI) - August 15 at 6:31 PM logoMerus Labs International : Reports Fiscal Q3 2016 Results (NASDAQ:MSLI) - August 15 at 8:30 AM logoMerus Labs to Present at U.S. Investor Conference and Announces Date of Fiscal Q3 2016 Earnings Release (NASDAQ:MSLI) - August 10 at 6:43 PM logoMerus Labs Appoints Two Senior Executives (NASDAQ:MSLI) - July 4 at 8:51 AM logoMerus Announces Reduced Leverage and Provides Business Update (NASDAQ:MSLI) - July 4 at 7:00 AM logoMerus Labs Appoints Two New Senior Executives (NASDAQ:MSLI) - June 30 at 4:00 PM logoMerus Labs International Inc. (NASDAQ:MSLI) Reports Yearly Sales Estimate At $93.125 - Investor Newswire (NASDAQ:MSLI) - May 26 at 11:49 AM logoMerus Labs International Inc. Announces Deemed Exercise of Special Warrants (NASDAQ:MSLI) - May 18 at 4:24 PM logoMerus Labs reports 2Q loss (NASDAQ:MSLI) - May 11 at 5:56 PM logoMerus Labs Reports Fiscal Q2 2016 Results (NASDAQ:MSLI) - May 11 at 4:00 PM logoMerus Announces Re-Election of Directors (NASDAQ:MSLI) - April 4 at 12:00 PM logoMarch 7, 2016 Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi (NASDAQ:MSLI) - April 4 at 12:00 PM logoMerus Labs Int'l (MSLI) to Acquire Three Cardiovascular Products from UCB in EUR 92M Deal (NASDAQ:MSLI) - February 2 at 2:12 PM logo2:55 pm Merus Labs to acquire UCB's rights to Elantan, Isoket and Deponit in Europe and select other markets for EUR92 mln; updates FY16 EBITDA guidance (shares halted) (NASDAQ:MSLI) - February 1 at 2:55 PM logoMERUS LABS INTERNATIONAL INC. Financials (NASDAQ:MSLI) - January 5 at 1:04 PM logoMerus Labs Announces Filing of Preliminary Base Shelf Prospectus (NASDAQ:MSLI) - July 10 at 7:00 AM logoMerus Labs Provides an Update on German Reimbursement Review (NASDAQ:MSLI) - June 3 at 4:00 PM


Merus Labs International (NASDAQ:MSLI) Chart for Friday, October, 28, 2016

Last Updated on 10/28/2016 by Staff